Overview:
Multiple myeloma (MM) is a type of blood cancer. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Plasma cells are an important part of the immune system, helping to fight a variety of infections and diseases. MM is a type of blood cancer and characterized by renal failure, low blood counts, hypercalcemia, monoclonal gammopathy, immune suppression, and anemia. Moreover, it remains an incurable disease. As reported by the American Cancer Society, in 2017, more than 30,280 new cases of multiple myeloma will be diagnosed in the United States and over 12,590 people will die from the disease. Furthermore, as reported by the National Center for Biotechnology Information (NCBI), MM represented 8.2% of all blood cancers in 2014 in Africa.
Get PDF Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/190
B-cell maturation antigen (BCMA) has become an important therapeutic target in MM. The expression profiles displayed by Transmembrane Activator and CAML Interactor (TACI) and BAFF-receptor (BAFF-R) are comparatively lower than those of BCMA in people with MM. Moreover, these antigens are rarely detected in malignant plasma cells, thus BCMA is preferred as a standard alternative over other antigens. Therefore, BCMA-targeted therapies have gained traction for cancer treatment and is the choice of treatment for MM. BCMA is an important therapeutic target in MM with three modalities of treatment in development, such as bispecific T-cell engagers (BITEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cell therapies (CAR T-cell therapies).
Drivers:
Increasing number of recurring cases of MM across the world is expected to augment growth of the global B-cell maturation Antigen (BCMA) targeted therapies market during the forecast period. Patients undergoing radiation therapy and chemotherapy are at higher risk of cancer recurrence because they develop resistance to these therapy. At this time, there is no cure for recurrent cancer and therefore BCMA targeted therapies provide successful therapeutic options for the treatment of recurrent MM.
Moreover, market players are focusing on developing and launching novel therapies (such as BITEs, ADCs, and CAR T-cell therapies), which in turn is drive to accelerate the global B-cell maturation Antigen (BCMA) targeted therapies market growth. For instance, GlaxoSmithKline Plc., in November 2017, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for GSK2857916 monotherapy in patients with multiple myeloma who have failed at least three prior lines of therapy, including an anti-CD38 antibody and are refractory to a proteasome inhibitor and an immunomodulatory agent.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/190
Restraints:
High cost of multiple combinational drug and high cost of maintenance therapy is expected to hamper the growth of the market.
Market Taxonomy:
By Product Type:
- CAR-T cell
- Bispecific Antibodies
- Antibody Drug Conjugates
By Indication:
- Acute Lymphoblastic Leukemia
- Multiple Myeloma
By Geography:
- North America
- South America
- Europe
- Asia Pacific
- Middle East
- Africa
Competitive Landscape:
Key players active in the global B-cell maturation Antigen (BCMA) targeted therapies market are Novartis AG, Celgene Corporation, Juno Therapeutics, Amgen Inc., Gilead Sciences. Inc., Affimed N.V, Autolus Ltd. Poseida Therapeutics, Inc., and GlaxoSmithKline plc.
Reasons to Buy this B-cell Maturation Antigen (BCMA) Targeted Therapies Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging B-cell Maturation Antigen (BCMA) Targeted Therapies market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging B-cell Maturation Antigen (BCMA) Targeted Therapies market
➡Leading company profiles reveal details of key B-cell Maturation Antigen (BCMA) Targeted Therapies market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging B-cell Maturation Antigen (BCMA) Targeted Therapies market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 Flat USD2000 Off
Buy This Complete Business Report @
https://www.coherentmarketinsights.com/promo/buynow/190
Table of Content
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Snapshot
- Market Dynamics, Opportunity, and Pipeline Analysis
- Market Dynamics
- Drivers
- Restraints
- Market opportunity
- Pipeline Analysis
- Targeted therapies developed till now
- Epidemiology
- Market Dynamics
- Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type
- Introduction
- Antibody Drug Conjugates
- Research Details
- CAR- T cells
- Research Details
- Bispecific Antibodies
- Research Details
- Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Indication
- Introduction
- Acute Lymphoblastic Leukemia
- Overview
- Multiple Myeloma
- Overview
- Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Regions
- Introduction
- Addressable Market
- North America
- Overview
- Epidemiology
- Latin America
- Overview
- Epidemiology
- Europe
- Overview
- Epidemiology
- Asia Pacific
- Overview
- Epidemiology
- Middle East
- Overview
- Epidemiology
- Africa
- Overview
- Epidemiology
- Introduction
- Company Profiles
- Celgene Corporation*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- GlaxoSmithKline plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Juno Therapeutics
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Gilead Sciences. Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Amgen Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Affimed N.V
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Poseida Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Autolus Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Analyst Views
- Celgene Corporation*
- Section
- References
- Research Methodology
- About Us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837